Feirza 1/20 Shortage: What Providers and Prescribers Need to Know in 2026

Patient calls about medication availability can disrupt clinic workflows and create urgent gaps in contraceptive coverage. This article is intended for OB/GYNs, primary care physicians, NPs, PAs, and other prescribers who have patients on Feirza 1/20 (norethindrone acetate 1 mg / ethinyl estradiol 20 mcg / ferrous fumarate 75 mg) and want to be prepared with accurate, actionable information.

Current Shortage Status (2026)

As of 2026, there is no FDA-declared national shortage of Feirza 1/20 or the norethindrone acetate/ethinyl estradiol/ferrous fumarate drug class. The FDA drug shortage database (fda.gov/drugs/drug-shortages) and ASHP shortage resource do not list this formulation as an active shortage. However, clinicians are seeing localized stock gaps driven by distribution factors specific to this brand's recent market entry (January 2025, NDC 70700-307, ANDA202772).

Xiromed LLC, the manufacturer, introduced Feirza 1/20 as a new generic brand. Its distribution footprint is still expanding, meaning it is not yet a preferred or high-inventory brand at every pharmacy. Patients may not be able to fill at their usual pharmacy even though the drug class itself is broadly available.

Clinical Significance: Why Prescription Continuity Matters

For patients using Feirza 1/20 for contraception, any interruption in active pill intake carries a real risk of unintended pregnancy. The 21 active tablets in each pack contain norethindrone acetate and ethinyl estradiol; missing even two consecutive active pills requires backup contraception for 7 days. Patients in week 1 of a new pack who miss pills are at highest risk.

For patients using Feirza 1/20 for acne management, interruptions disrupt the hormonal cycle that reduces androgenic stimulation of sebaceous glands. Abrupt discontinuation won't cause acute harm, but patients may experience acne recurrence, breakthrough bleeding, or hormonal fluctuation symptoms.

Therapeutic Equivalents: What You Can Substitute Without Clinical Concern

The following products are FDA-approved as therapeutically equivalent to Feirza 1/20 — same active ingredients, same doses, same 21/7 cycle structure:

Junel Fe 1/20 (28 Day) — norethindrone acetate 1 mg / EE 20 mcg / ferrous fumarate 75 mg

Blisovi Fe 1/20 (28 Day) — same formulation, different manufacturer

Larin Fe 1/20 (28 Day) — same formulation, Mayne Pharma/Allergan

Microgestin Fe 1/20 (28 Day) — same formulation, Mayne Pharma

Hailey Fe 1/20 (28 Day) — same formulation, Afaxys

Aurovela Fe 1/20 (28 Day) — same formulation, Aurobindo

Recommended prescribing strategy: Write the prescription as "norethindrone acetate 1 mg / ethinyl estradiol 20 mcg / ferrous fumarate 75 mg tablets — dispense as written or any equivalent generic — 28-day pack" to allow pharmacy-level substitution without requiring a new prescription call for each brand switch.

When Should You Not Substitute Directly?

Direct substitution to an equivalent generic is appropriate in most cases. Situations requiring more clinical judgment include:

Patient is mid-cycle and the available substitute has a different cycle structure (e.g., 24/4 vs 21/7) — counsel the patient on how to restart or bridge.

Patient has a history of sensitivity to specific inactive ingredients — although inactive excipients differ by manufacturer, clinically significant reactions to excipients in these generic formulations are rare.

Prescription was written brand-specific for a clinical reason (e.g., specific progestin sensitivity, androgenicity concerns) — review before substituting with a different progestin type.

Proactive Prescribing: Reducing Future Access Issues

Several prescribing practices can reduce the likelihood of patients experiencing access gaps:

Write for the generic drug class, not the brand: "norethindrone acetate 1 mg / ethinyl estradiol 20 mcg / ferrous fumarate 75 mg" allows pharmacists to dispense whichever brand is in stock.

Prescribe 90-day supplies: Reduces refill frequency, builds buffer, and many insurance plans offer lower copays for 90-day fills.

Recommend mail-order for stable patients: Mail-order pharmacies typically carry larger, more consistent inventory and may be the most reliable supply source.

Counsel patients to refill at 7–10 days remaining: This provides enough lead time to locate stock or request a substitution without any pill gap.

Patient Communication Templates

When advising patients who can't find Feirza 1/20, consider this communication framework:

"Feirza 1/20 and [equivalent generic name] contain the same active hormones at the same dose and work exactly the same way. I am updating your prescription so your pharmacist can fill whichever is available."

"Do not skip your active white pills while waiting for your prescription to be filled — this can reduce the pill's effectiveness. If you've already missed pills, contact us and we'll advise you on backup contraception."

Referring Patients to Additional Resources

medfinder is a service that helps patients locate their prescriptions at nearby pharmacies. Rather than patients spending hours calling pharmacies, medfinder calls on their behalf and texts them results. Visit medfinder.com/providers to learn how medfinder supports patient medication access.

Clinical Summary

Feirza 1/20 is not in a declared shortage as of 2026, but its recent market entry creates localized stock gaps. The drug class has robust generic competition, making therapeutic substitution straightforward for most patients. Proactive prescribing practices — generic-class prescriptions, 90-day supplies, mail-order referrals — are the most effective way to prevent patient access disruptions. See our companion guide on how to help your patients find Feirza 1/20 for more practical strategies.